These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 19858398

  • 1. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.
    Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, Allan JM, Parmar MK, Quirke P, Seymour MT.
    J Clin Oncol; 2009 Nov 20; 27(33):5519-28. PubMed ID: 19858398
    [Abstract] [Full Text] [Related]

  • 2. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.
    Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, Chibaudel B, Formento JL, Francoual M, Lledo G, André T, Mabro M, Mineur L, Flesch M, Carola E, de Gramont A.
    Br J Clin Pharmacol; 2010 Jan 20; 69(1):58-66. PubMed ID: 20078613
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
    Smorenburg CH, Peters GJ, van Groeningen CJ, Noordhuis P, Smid K, van Riel AM, Dercksen W, Pinedo HM, Giaccone G.
    Ann Oncol; 2006 Jan 20; 17(1):35-42. PubMed ID: 16251201
    [Abstract] [Full Text] [Related]

  • 4. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.
    Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, Barrett JH, Selby P, Meade AM, Stephens RJ, Parmar MK, Seymour MT.
    J Clin Oncol; 2008 Jun 01; 26(16):2690-8. PubMed ID: 18509181
    [Abstract] [Full Text] [Related]

  • 5. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.
    Glimelius B, Garmo H, Berglund A, Fredriksson LA, Berglund M, Kohnke H, Byström P, Sørbye H, Wadelius M.
    Pharmacogenomics J; 2011 Feb 01; 11(1):61-71. PubMed ID: 20177420
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
    Falvella FS, Cheli S, Martinetti A, Mazzali C, Iacovelli R, Maggi C, Gariboldi M, Pierotti MA, Di Bartolomeo M, Sottotetti E, Mennitto R, Bossi I, de Braud F, Clementi E, Pietrantonio F.
    Br J Clin Pharmacol; 2015 Sep 01; 80(3):581-8. PubMed ID: 25782327
    [Abstract] [Full Text] [Related]

  • 9. Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.
    Ishida H, Fujita K, Akiyama Y, Sunakawa Y, Yamashita K, Mizuno K, Miwa K, Kawara K, Ichikawa W, Ando Y, Saji S, Sasaki Y.
    Jpn J Clin Oncol; 2011 May 01; 41(5):617-23. PubMed ID: 21310730
    [Abstract] [Full Text] [Related]

  • 10. 5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX.
    Onesti CE, Botticelli A, La Torre M, Borro M, Gentile G, Romiti A, Lionetto L, Petremolo A, Occhipinti M, Roberto M, Falcone R, Simmaco M, Marchetti P, Mazzuca F.
    Anticancer Drugs; 2017 Mar 01; 28(3):322-326. PubMed ID: 27845948
    [Abstract] [Full Text] [Related]

  • 11. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
    Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz HJ.
    Br J Cancer; 2004 Jul 19; 91(2):344-54. PubMed ID: 15213713
    [Abstract] [Full Text] [Related]

  • 12. Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma.
    Puerta-García E, Urbano-Pérez D, Carrasco-Campos MI, Pérez-Ramírez C, Segura-Pérez A, Calleja-Hernández, Cañadas-Garre M.
    Surg Oncol; 2020 Dec 19; 35():388-398. PubMed ID: 33035787
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
    Delaunoit T, Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Findlay BP, Thomas SP, Salim M, Schaefer PL, Stella PJ, Green E, Mailliard JA.
    Cancer; 2004 Nov 15; 101(10):2170-6. PubMed ID: 15470715
    [Abstract] [Full Text] [Related]

  • 17. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.
    Health Technol Assess; 2008 May 15; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [Abstract] [Full Text] [Related]

  • 18. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.
    Kristensen MH, Pedersen PL, Melsen GV, Ellehauge J, Mejer J.
    J Int Med Res; 2010 May 15; 38(3):870-83. PubMed ID: 20819423
    [Abstract] [Full Text] [Related]

  • 19. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
    Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts S.
    J Clin Oncol; 2006 Jul 20; 24(21):3347-53. PubMed ID: 16849748
    [Abstract] [Full Text] [Related]

  • 20. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
    Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M.
    J Clin Oncol; 2007 Apr 01; 25(10):1247-54. PubMed ID: 17401013
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.